Co-Founder, President, CEO and Director
Before co-founding CoDa, Mr. Duft was a partner in the Duane Morris law firm. From 1990 through 1998, Mr. Duft was Senior Vice President and General Counsel of Amylin Pharmaceuticals. His 25 year legal practice focused on biotechnology company strategy and growth, with an emphasis on intellectual property licensing, strategic patent prosecution, and litigation. In addition to experience in crafting and building U.S. and worldwide patent portfolios, Mr. Duft has drafted and negotiated numerous agreements, including local and worldwide joint research agreements, joint development agreements and corporate partnership agreements, as well as numerous licenses. Mr. Duft is a graduate of the George Washington University Law School, where he received a Masters in Patent and Trade Regulation, (LL.M., with highest honors), the California Western School of Law (J.D., cum laude ) , and the University of Colorado where he received his degree in Molecular, Cellular and Developmental Biology.
Chief Operating Officer
Before joining CoDa, Mr. Campbell was a venture principal with Sorrento Associates, Inc., a San Diego-based venture capital firm, from 2001 to 2005. Over the last 14 years, Mr. Campbell has worked with emerging companies in San Diego as a founder, CEO, director, corporate attorney, general counsel and vice president of business development. While a venture principal, Mr. Campbell served as a director of Cameron Health, Inc., Laser Diagnostic Technologies, Inc., and V-Enable, Inc. Sorrento participated in venture investment syndicates in Idun Pharmaceuticals, Inc. (acquired by Pfizer) where Mr. Campbell was a board observer and in Torrey Pines Therapeutics (NASDAQ: TPTX). Mr. Campbell earned a J.D. from the University of San Diego (Magna Cum Laude) an M.B.A. from UCLA (with honors) and a B.A. in Biology with Honors Distinction from Boston University (Summa Cum Laude, Phi Beta Kappa).
Vice President – Commercialization
Grove Matsuoka joined CoDa Therapeutics November 2007 as Vice President Commercialization. Mr. Matsuoka brings his 20 years of drug development experience across Research & Development as well as Sales & Marketing to assist CoDa Therapeutics in commercializing novel wound healing therapeutics. Prior to CoDa, Grove lead a Strategic Planning and Operations Group within Amgen’s Medical Affairs Function and was Head of Amgen’s Development Project Management Department for a number of years. While at Sandoz Pharmaceuticals (Novartis) and Immulogic Corporation, Grove obtained increasing commercial responsibilities in Field Sales and Product Management. Grove received his MBA from Boston College and his Bachelor’s Degree in Microbiology and Immunology from University of California at Berkeley.
Vice President - Manufacturing
Andrew Knudten, joined CoDaUS in October 2007 as Vice President of Manufacturing. Mr. Knudten, a seasoned biotechnology executive, brings over 15 years of biotechnology manufacturing, product development and operational experience to CoDa. Mr. Knudten joins CoDa after 13 years at Amgen, Inc. where he held a number of key operating positions. Most recently, Andrew served as director of operations and manufacturing in Boulder, Colorado where he was responsible for the manufacture of clinical and commercial material. Prior positions at Amgen encompassed a variety of roles including operations planning and strategy, product development, project management, corporate process improvement, finance, and discovery research. Prior to Amgen, Andrew spent two years at Dekalb Plant Genetics in Mystic, Connecticut where he managed protein purification and characterization activities. Mr. Knudten received his MBA from the Anderson School at UCLA and his M.S. in Cell Biology and Genetics from the University of Nebraska.
Back to Top
